Hu Y, Zhong A, Yang X
Hubei Cancer Hospital, Wuhan 430079, China.
Zhonghua Zhong Liu Za Zhi. 2000 Jan;22(1):30-1.
To judge the prognostic value of serum CA125 level in patients with advanced non-small cell lung cancer.
Sixty-six untreated patients with advanced non-small cell lung cancer (NSCLC) confirmed histologically were studied. They received two to four cycles of chemotherapy, some of them combined with radiotherapy. All these patients were assayed for serum CA125 before treatment. The cut-off value of serum CA125 level was 35 U/ml.
Increased serum CA125 levels were observed in 24 out of 66 patients (36.4%). Patients with increased serum CA125 levels had an average survival rate of 12.5% at 1 year and 0 at 2 years, whereas that of patients with normal serum CA125 levels was of 57.1% at 1 years, 14.3% at 2 years and 7.1% at 3 years. Cox proportion hazard multivariate analysis showed that the prognosis of patients was related to serum CA125 levels (P = 0.000) and effects of treatment (P = 0.046).
CA125 can be used as an independent prognostic parameter in advanced NSCLC.
判断血清CA125水平对晚期非小细胞肺癌患者的预后价值。
对66例经组织学确诊的未经治疗的晚期非小细胞肺癌（NSCLC）患者进行研究。他们接受了2至4个周期的化疗，部分患者联合放疗。所有患者在治疗前均检测血清CA125。血清CA125水平的临界值为35 U/ml。
66例患者中有24例（36.4%）血清CA125水平升高。血清CA125水平升高的患者1年平均生存率为12.5%，2年为0；而血清CA125水平正常的患者1年生存率为57.1%，2年为14.3%，3年为7.1%。Cox比例风险多因素分析显示，患者的预后与血清CA125水平（P = 0.000）和治疗效果（P = 0.046）有关。
CA125可作为晚期NSCLC的独立预后参数。
